Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Enasidenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Health Canada Issues Recall of IDHIFA (enasidenib mesylate)
    Health Canada Issues Recall of IDHIFA (enasidenib mesylate)

    08 Jun 2023

    // HEALTH CANADA

    https://recalls-rappels.canada.ca/en/alert-recall/idhifa-enasidenib-mesylate-market-withdrawal-and-continued-access

    HEALTH CANADA
    08 Jun 2023
    Share Share
    Bristol Myers Squibb's targeted AML drug Idhifa fails to extend patients' lives
    Bristol Myers Squibb's targeted AML drug Idhifa fails to extend patients' lives

    25 Aug 2020

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/marketing/bristol-myers-squibb-s-ex-celgene-aml-drug-idhifa-fails-to-extend-patients-lives

    Angus Liu FIERCEPHARMA
    25 Aug 2020
    Share Share
    Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial
    Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial

    25 Aug 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200825005224/en

    BUSINESSWIRE
    25 Aug 2020
    Share Share
    Agios, seeking a new strategy, touts positive data and marketing deal
    Agios, seeking a new strategy, touts positive data and marketing deal

    13 Jun 2020

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/agios-mitapivat-royalty-deal/579749/

    Jacob Bell BIOPHARMADIVE
    13 Jun 2020
    Share Share
    Medicare Part D no match for runaway specialty drug costs: study
    Medicare Part D no match for runaway specialty drug costs: study

    07 Feb 2019

    // Mark Miller REUTERS

    https://www.reuters.com/article/us-column-miller-medicare/medicare-part-d-no-match-for-runaway-specialty-drug-costs-study-idUSKCN1PW16X

    Mark Miller REUTERS
    07 Feb 2019
    Share Share
    Agios wins FDA nod for targeted AML drug Tibsovo
    Agios wins FDA nod for targeted AML drug Tibsovo

    23 Jul 2018

    // E. Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/agios-wins-fda-nod-for-targeted-aml-drug-tibsovo

    E. Sagonowsky FIERCE PHARMA
    23 Jul 2018
    Share Share